糖尿病性胃アトニー:治療薬開発パイプライン動向(2014年下半期)

◆英語タイトル:Diabetic Gastroparesis - Pipeline Review, H2 2014
◆商品コード:GMDHC5289IDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2014年7月15日
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥228,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥684,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。



【レポートの概要】

Diabetic Gastroparesis – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Diabetic Gastroparesis – Pipeline Review, H2 2014’, provides an overview of the Diabetic Gastroparesis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Diabetic Gastroparesis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Gastroparesis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Diabetic Gastroparesis Overview 6
Therapeutics Development 7
Pipeline Products for Diabetic Gastroparesis – Overview 7
Pipeline Products for Diabetic Gastroparesis – Comparative Analysis 8
Diabetic Gastroparesis – Therapeutics under Development by Companies 9
Diabetic Gastroparesis – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Diabetic Gastroparesis – Products under Development by Companies 13
Diabetic Gastroparesis – Companies Involved in Therapeutics Development 14
GlaxoSmithKline plc 14
Shire Plc 15
Evoke Pharma, Inc. 16
Targacept, Inc. 17
Cempra, Inc. 18
RaQualia Pharma Inc. 19
Rhythm Pharmaceuticals 20
Diabetic Gastroparesis – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
metoclopramide hydrochloride – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
prucalopride succinate – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
camicinal – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
relamorelin – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
velusetrag – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
TC-6499 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
RQ-00201894 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Agonize Motilin Receptor for Gastric Disorders – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Diabetic Gastroparesis – Recent Pipeline Updates 42
Diabetic Gastroparesis – Dormant Projects 49
Diabetic Gastroparesis – Discontinued Products 50
Diabetic Gastroparesis – Product Development Milestones 51
Featured News & Press Releases 51
Jun 25, 2014: Targacept Initiates Exploratory Study of TC-6499 in Diabetic Gastroparesis 51
May 28, 2014: Evoke Pharma Secures $4.5 Million Loan Facility With Square 1 Bank 51
May 06, 2014: Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis 52
Jan 22, 2014: Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics 53
Oct 15, 2013: Targacept Scientists to Present Data On TC-6499 at Society for Neuroscience Satellite Meeting 54
May 20, 2013: Rhythm Announces Phase Ib Results For Ghrelin Prokinetic RM-131 For Gastroparesis In Patients With Type 1 Diabetes 54
Oct 22, 2012: Rhythm Announces Positive Phase I Results For Ghrelin Prokinetic RM-131 For Treatment Of Diabetic Gastroparesis 55
Jun 06, 2012: Rhythm Initiates Phase II Clinical Trial Of Ghrelin Prokinetic RM-131 For Diabetic Gastroparesis 56
May 22, 2012: Rhythm Announces Phase Ib Results Of RM-131 For Diabetic Gastroparesis 56
May 09, 2011: Rhythm’s RM-131 Restores Gastrointestinal Function As Potent Ghrelin Prokinetic 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products under Development for Diabetic Gastroparesis, H2 2014 7
Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Diabetic Gastroparesis - Pipeline by GlaxoSmithKline plc, H2 2014 14
Diabetic Gastroparesis - Pipeline by Shire Plc., H2 2014 15
Diabetic Gastroparesis - Pipeline by Evoke Pharma, Inc., H2 2014 16
Diabetic Gastroparesis - Pipeline by Targacept, Inc., H2 2014 17
Diabetic Gastroparesis - Pipeline by Cempra, Inc., H2 2014 18
Diabetic Gastroparesis - Pipeline by RaQualia Pharma Inc., H2 2014 19
Diabetic Gastroparesis - Pipeline by Rhythm Pharmaceuticals, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Diabetic Gastroparesis Therapeutics - Recent Pipeline Updates, H2 2014 42
Diabetic Gastroparesis - Dormant Projects, H2 2014 49
Diabetic Gastroparesis - Discontinued Products, H2 2014 50

List of Figures
Number of Products under Development for Diabetic Gastroparesis, H2 2014 7
Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Top 10 Target, H2 2014 22
Number of Products by Stage and Top 10 Target, H2 2014 23
Number of Products by Top 10 Mechanism of Action, H2 2014 24
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 25
Number of Products by Top 10 Route of Administration, H2 2014 26
Number of Products by Stage and Top 10 Route of Administration, H2 2014 27
Number of Products by Top 10 Molecule Type, H2 2014 28
Number of Products by Stage and Top 10 Molecule Type, H2 2014 29

【掲載企業】

GlaxoSmithKline plc
Shire Plc
Evoke Pharma, Inc.
Targacept, Inc.
Cempra, Inc.
RaQualia Pharma Inc.
Rhythm Pharmaceuticals

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[糖尿病性胃アトニー:治療薬開発パイプライン動向(2014年下半期)]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月06日現在 219,162 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆